Eric Low is the Chief Executive at Myeloma UK.
Amongst a very busy portfolio of projects, Eric’s recent achievements have included establishing a national Myeloma Clinical Trial Network and a myeloma genetics and drug development research partnership with The Institute of Cancer Research in London. Eric has also helped to ensure that myeloma patients in the UK have been able to access novel treatments through advocating solution-oriented approaches to the way drugs are made available on the NHS.
Eric currently has a particular interest in drug pricing, as well as developing innovative ways to translate the outcomes of research into clinical practice. He is also currently working on a number of initiatives including the development of an outcomes registry, state of the art treatment pathways and a myeloma bio-banking strategy.
He is an active member of a number of myeloma and cancer-related boards, steering groups and committees.
Eric spends much of his time out and about meeting with representatives from the myeloma community, tirelessly campaigning on behalf of myeloma patients for the very best standards of treatment and care. Through his passion and enthusiasm he has significantly raised the profile of myeloma in the medical, political and media arena.
Eric was awarded an OBE for services to charity as Chief Executive, Myeloma UK in the Queen’s Birthday Honours 2012.